AIM: The present study was aimed to investigate NKD2 expression as well as promoter methylation and further analyze their clinical significance in patients with acute myeloid leukemia (AML).
Introduction
Acute myeloid leukemia (AML) is a complex cancer characterized by uncontrolled proliferation and apoptosis of abnormal stem cells in the bone marrow (BM) and inhibition in the growth of normal hematopoietic cells [1, 2] . The diagnosis of AML mainly depends on the features of morphology, immunology, cytogenetics, and molecular biology (MICM). Despite the advancements in the treatment of leukemia, clinical outcome of AML remains unsatisfactory [3] . Cytogenetic alterations play crucial roles in the pathogenesis of AML and also act as vital biological markers in predicting prognosis for AML
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International Publisher [4, 5] . However, there are approximately 40% de novo AML patients do not have clonal cytogenetic abnormalities, which was defined as cytogenetically normal AML (CN-AML) [6, 7] . Clinical outcome of CN-AML patients is quite heterogeneous from a few days to complete cure. Recently, several molecular biomarkers including NPM1, CEBPA, C-KIT, and FLT3 mutations have provided helpful prognostic information for these patients [8] . Therefore, identifying novel genetic and epigenetic alterations which can recognize the patients who are at the risk of poor outcome is warranted to optimize treatment strategies [9, 10] .
WNT/β-Catenin signaling pathway plays crucial roles in physiological processes including stem cell maintenance, cell differentiation, migration, apoptosis and proliferation during embryonic development [11, 12] . At the same time, abnormal regulation of Wnt/β-catenin signaling pathway also contributes to the development of human cancers including leukemia. Increasing studies have indicated that dysregulated Wnt pathway is associated with leukemogenesis and clinical outcome [13] [14] [15] [16] . Overexpression of Wnt/β-catenin pathway genes or loss of Wnt antagonists promotes uncontrolled cell growth and survival [17] . Naked family (NKD1 and NKD2) has been reported to function as a negative regulator of Wnt/β-catenin signaling pathway [18] . NKD binds and inactivates dishevelled, a scaffold protein that transduces the Wnt signal from the frizzled receptor to the destruction complex [19] . Decreased expression of NKD2 caused by its promoter hypermethylation has been increasingly demonstrated in several solid tumors [19] [20] [21] [22] . However, the pattern of NKD2 expression and methylation in AML has not been explored yet. Therefore, we focused on the NKD2 expression as well as methylation and their clinical significance in de novo patients with AML in the current study.
Materials and methods

Patients' samples
A total of 113 patients with a diagnosis of de novo AML including 42 CN-AML were enrolled into the study approved by the Institutional Review Board of the Affiliated People's Hospital of Jiangsu University. The diagnosis and classification of the patients were based on the revised 2008 World Health Organization (WHO) criteria [23] . Clinical features of the patients were showed in Table 1 . Treatment protocol for AML patients was described previously [24] . A total of 9 AML patients achieved complete remission (CR) after induction therapy together with 24 healthy donors were also included. Follow-up data was obtained in 94 patients ranging from 1 to 58 months with a median of 7 months. Bone marrow (BM) were collected form all the patients and participants after written informed consents were obtained. 
Cell line, cell culture and 5-aza-dC treatment
Human leukemic cell line (THP1) was cultured in 1640 medium containing 10% fetal calf serum (ExCell Bio, Shanghai, China) and grown at 37°C in 5% CO2 humidified atmosphere. For epigenetic studies, 5-aza-2'-deoxycytidine (5-aza-dC) (Sigma-Aldrich, Steinheim, USA) diluted in dimethyl sulfoxide (DMSO) was added in three flasks of THP1 cells (at a density of 5×10 5 cells/ml in 10 ml) once a day at different final concentrations of 0 μM, 2 μM and 4 μM during 3 days. All cells were cultured until harvested for extraction of RNA and DNA.
RNA isolation, reverse transcription and RQ-PCR
BM mononuclear cells (BMMNCs) were extracted by Lymphocyte Separation Medium (TBD sciences, Tianjin, China). Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription (RT) was performed as reported previously [25, 26] .
Real-time quantitative PCR (RQ-PCR) was performed on a 7500 Thermo cycler (Applied Biosystems, CA, USA). The reaction system with 20 μL volume consisted of H2O 6 μL, 10 μM of AceQ qPCR SYBR Green Master Mix (Vazyme Biotech Co., Piscataway, NJ, USA), 0.4 μM of ROX Reference Dye 2 (Invitrogen, Carlsbad, CA,USA),and 0.8 μM of primers (forward 5'-ACAGGAGGTTGTCTGCA CACG-3' and reverse 5'-GACTTGAGGAACTG CTTCTCCG-3') [20] . The RQ-PCR reaction conditions were 95 °C for 5 min, followed by 40 cycles at 95 °C for 10 s, 65 °C for 30 s, 72 °C for 32 s, and 86 °C for 32 s to collect fluorescence, finally followed by 95 °C for 15 s, 60 °C for 60 s, 95 °C for 15 s, and 60 °C for 15 s. Both positive and negative controls were included in each assay. Relative NKD2 expression levels were calculated using the following equation:
DNA isolation, chemical modification and RQ-MSP
Genomic DNA was isolated using genomic DNA purification kit (Gentra, Minneapolis, MN, USA) and was modified using the CpGenome DNA Modification Kit (Chemicon, Ternecula, Canada) according to the manufacturer's instructions. promoter methylation in samples. NM-NKD2 was calculated using the following formula:
BSP
Bisulfite sequencing PCR (BSP) reaction system was composed of 1×PCR buffer (KCl 0.25 mM), dNTP Mixture 6.25 μM, primers 0.5 μM, hot start DNA polymerase 0.75 U (Takara, Tokyo, Japan), and modified DNA 20 ng. The primers for bisulfite modified NKD2 promoter were 5'-TTTTGGAGTTAG TAGTGGGGG-3' (forward) and 5'-CACCAAAAA CAACTCTAACACC-3' (reverse). The program was carried out at 98°C for 10 s, 40 cycles for 10 s at 98°C, 30 s at 58°C, 72°C for 30 s, and followed by a final 7 min extension step at 72°C. The PCR products were analyzed on 2% agarose gels. Each purified product was cloned into pMD19-T Vector (Takara, Tokyo, Japan), and was transfected into DH5α competent cells (Vazyme Biotech Co., Piscataway, NJ, USA). Five clones from each sample were sequenced (BGI Tech Solutions Co., Shanghai, China).
HRMA and sequencing
High-resolution melting analysis (HRMA) was performed on the LightScanner platform (Idaho Technology Inc., Salt Lake City, Utah, USA). NRAS or KRAS, DNMT3A, IDH1/2, KIT, and NPM1 mutations were detected by HRMA [27] [28] [29] [30] . All positive samples were confirmed by DNA direct sequencing. FLT3-ITD and CEBPA mutations were detected by direct DNA sequencing (BGI Tech Solutions Co., Shanghai, China) [31] .
Statistical analyses
Statistical analyses were performed using the SPSS 20.0 software package. Mann-Whitney's U test was carried to compare the difference of continuous variables between two groups. Pearson Chi-square analysis or Fisher exact test was employed to compare the difference of categorical variables. Correlation analysis between NKD2 expression and prognosis was performed by Kaplan-Meier curves and Cox regression analysis. Receiver operating characteristic curve (ROC) and area under the ROC curve (AUC) were used to assess the value of NKD2 expression in discriminating AML patients from controls. For all analyses, a two-tailed P<0.05 was defined as statistically significant.
Results
NKD2 expression in AML patients
NKD2 transcript level in AML patients (range 0.0000-57.9485, median 0.0000) was significantly lower as compared with controls (range 0.0000-3.6715, median 0.0082) which indicated that NKD2 expression was down-regulated in AML (P=0.039, Fig. 1 ).
Discriminative capacity of NKD2 expression
ROC curve indicated that NKD2 expression might serve as a biomarker for distinguishing whole-cohort AML patients from normal controls (AUC=0.628, 95% CI: 0.515-0.740, P=0.049, Fig. 2 ). 
NKD2 methylation in AML patients
NKD2 methylation was detected in 101 AML patients and 24 controls with available DNA. NKD2 methylation level in AML patients (median 0.0009, range 0.0000-25.2199) was significantly higher than controls (median 0.0005, range 0.0000-1.0000) (P=0.044, Fig. 3 ) which suggested that NKD2 was hypermethylated in AML.
To further confirm RQ-MSP result, we selected 6 samples (2 with lowest methylation level, 2 with highest methylation level, and 2 selected randomly) to investigate the NKD2 methylation density by BSP. Controls presented almost fully unmethylated NKD2 promoter, while the two methylated AML patients presented higher density of NKD2 methylation (Fig.  4) . Moreover, NKD2 methylation density in the tested samples was heavily correlated with NKD2 methylation level (R=0.928, P=0.008). 
NKD2 expression was regulated by its promoter methylation
To determine the role of NKD2 promoter methylation in regulating NKD2 expression in AML, we analyzed the relationship between NKD2 methylation and expression in AML patients. Significantly negative correlation was observed between NKD2 expression and its promoter methylation in AML patients (R=-0.218, P=0.029, Fig. 5) .
We further selected NKD2-methylated THP1 cell line treated by 5-aza-dC to further verify the epigenetic mechanism. Before 5-aza-dC treatment, THP1 showed weakly NKD2 expression and highly methylated NKD2 promoter. As expected, NKD2 promoter methylation level was decreased, meanwhile, NKD2 expression was significantly up-regulated after 5-aza-dC treatment (Fig. 6) . 
Clinical and laboratory characteristics of AML patients
The whole cohort of AML patients were divided into two groups at the median level of NKD2 expression: low NKD2 expression (NKD2 low ) and high NKD2 expression (NKD2 high ). The correlation between NKD2 expression and clinical characteristics was presented in Table 1 . There were no significant differences in sex, age, platelets, white blood cells, hemoglobin and BM blasts between the NKD2 high and NKD2 low groups (P>0.05). No significant differences were found between the two groups in the distribution of WHO subtypes, and karyotypic classifications. Moreover, no significant correlations were found between NKD2 expression and nine gene mutations (P>0.05).
Correlation between NKD2 expression and clinical outcome
After induction therapy, there was no significant difference in complete remission (CR) rate between NKD2 low patients and NKD2 high patients (P=0.419, Table 1 ). Moreover, no significant differences were found between the two groups among both non-APL AML [30% (11/26) (Table 2 and 3) .
Furthermore, the prognostic impact of NKD2 expression was also confirmed by gene expression profiling (GEP) data (accession number GSE12417, http://www.ncbi.nlm.nih.gov/geo/) from two independent cohorts of adult CN-AML patients published by Metzeler et al using the online web tool Genomicscape (http://genomicscape.com/ microarray/survival.php) [32] . Similarly, patients with low NKD2 expression showed shorter OS as compared to those with high NKD2 expression in both two cohorts (162 and 78 patients) (P=0.033 and 0.053, respectively, Fig. 8a and 8b) .
Surveillance of NKD2 expression in follow-up AML patients
To further investigated whether levels of NKD2 factored in patients' response to therapy, we followed NKD2 expression of 9 patients with AML from the initial diagnosis to CR. Our study revealed that NKD2 showed significantly increased level in post-CR than initial diagnosis in follow-up AML patients (P=0.024, Fig 9) . 
Discussion
The activity of the Wnt pathway is controlled by extracellular and intracellular inhibitors mainly including secreted frizzled-related proteins (SFRPs), dickkopfs (DKK), SRY-box containing gene (SOX), and NKD family [19] . Frequent promoter hypermethylation of Wnt pathway inhibitor genes and their effect on gene expression have been revealed in malignant tumors [19] . Recently, accumulating evidence has revealed the direct role of NKD2 in tumorigenesis. Reduced NKD2 expression is found in osteosarcoma and has a significant role in driving tumor growth and metastasis [33] . NKD2 suppresses breast cancer cell proliferation both in vitro and in vivo and induced G1/S arrest and inhibits Wnt signaling in breast cancer cells [20] . In human gastric cancer, NKD2 restoration suppresses cell proliferation, colony formation, cell invasion and migration, induced G2/M phase arrest, and sensitizes cancer cells to docetaxel [34] . In addition, curcumin significantly upregulated the expression of NKD2 in SW620 colorectal cancer cells and inhibited the proliferation of colorectal cancer cells, resulting in the down-regulation of crucial markers in the Wnt signaling [35] . Zhi Li et al suggested that NKD2 is a direct target of miR-130b, and miR-130b regulated proliferation and apoptosis of osteosarcoma cells by targeting NKD2 and regulating the Wnt signaling [36] . Moreover, long noncoding RNA ZFAS1 repressed underlying targets KLF2 and NKD2 transcription to promote gastric cancer cells proliferation by interacting with EZH2 and LSD1/CoREST [37] . Our previous studies have disclosed that SOX17 and SRFP1/2 expression was down-regulated in AML and low SOX17 expression was associated with adverse prognosis in CN-AML patients [38] [39] [40] . Additionally, decreased SFRP1 expression was found more frequently in the less well differentiated subgroups of AML and is associated with NPM1 mutation in AML [39] , whereas reduced SFRP2 expression was correlated with intermediate/poor karyotypes in AML [40] . As far as we know, this is the first report about NKD2 expression and its clinical significance in patients with AML.
In this study, we observed that down-regulation of NKD2 expression was a frequent event in AML patients, which indicates that NKD2 might act as tumor suppressor role as well in leukemogenesis. Obviously, function studies of NKD2 in leukemia are needed to support our results. Although no significant associations were observed between NKD2 expression and laboratory features as well as common gene mutations, survival analyses revealed that low NKD2 expression were associated with shorter OS and LFS among CN-AML patients. Notably, dynamic monitoring the level of NKD2 in 9 cases of patients illustrated that NKD2 were significantly increased from the initial diagnosis to CR by mentioned therapeutic protocols. In recent years, clinical significance of NKD2 expression has been increasingly investigated in various human cancers. Zhao et al demonstrated that decreased expression of NKD2 was associated with a significantly worse OS in human osteosarcoma tumors [33] . These results together indicated that NKD2 expression was a valuable predictor in assessing treatment outcome as well as status, and might serve as a criterion for the therapeutic evaluation in AML.
The regulation of NKD2 expression is associated with the methylation of its promoter [21] . We found that NKD2 methylation was a common event in AML patients and its role in silencing NKD2 expression was confirmed in leukemic cell lines THP1. In addition, our study further observed that NKD2 expression was negatively correlated with NKD2 expression in clinical samples. Recently, the clinical significance of NKD2 methylation has been also identified in several cancers [20, 21, 34] . In human breast cancer, NKD2 methylation is associated with higher tumor stages [20] . Moreover, in gastric cancer, methylation of NKD2 is significantly associated with the degree of cell differentiation, TNM stage, and distant metastasis and may serve as a poor prognostic predictor [34] .
All in all, decreased NKD2 expression inactivated by promotor hypermethylation is a common event in AML and is associated with adverse outcome in CN-AML patients.
